

# Consolidated Statement of Comprehensive Income

Mitsubishi Tanabe Pharma Corporation and Consolidated Subsidiaries

(Millions of yen)

	FY 2017	FY 2018
<b>Profit for the year</b>	53,992	<b>32,216</b>
<b>Other comprehensive income</b>		
Items that will not be reclassified subsequently to profit or loss		
Net changes in financial assets measured at fair value through other comprehensive income	4,542	<b>4,170</b>
Remeasurements of defined benefit plans	5,823	<b>(780)</b>
Subtotal	10,365	<b>3,390</b>
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	(8,798)	<b>5,304</b>
Effective portion of changes in fair value of cash flow hedges	1,033	—
Share of other comprehensive income of associates and joint ventures accounted for using equity method	28	<b>(16)</b>
Subtotal	(7,737)	<b>5,288</b>
Other comprehensive income (loss), net of tax	2,628	<b>8,678</b>
<b>Comprehensive income</b>	56,620	<b>40,894</b>
<b>Comprehensive income (loss) attributable to:</b>		
Owners of the Company	60,861	<b>46,169</b>
Non-controlling interests	(4,241)	<b>(5,275)</b>
Comprehensive income	56,620	<b>40,894</b>

Value Creation  
StoryBusiness and  
Financial StrategyNon-Financial  
InformationOperating Results and  
Data